Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.51 |
| ▸ | GRIN2B | Q13224 | 6/20 | 0.50 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.50 |
| ▸ | GRIN2D | O15399 | 3/20 | 0.50 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.50 |
| ▸ | GRIN2C | Q14957 | 3/20 | 0.50 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.50 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 5/20 | 0.48 |
| ▸ | HTR2A | P28223 | 5/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.48 |
| ▸ | HTR2B | P41595 | 4/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.48 |
| ▸ | HTR1A | P08908 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15196695 | 1.00 | CYP3A4 (0.56) | CYP3A4ALDH1A1TSHRCYP2C19KCNA5 | |
| SCHEMBL12568682 | 1.00 | CYP3A4 (0.56) | CYP3A4ALDH1A1TSHRCYP2C19KCNA5 | |
| SCHEMBL514982 | 1.00 | CYP3A4 (0.56) | CYP3A4ALDH1A1TSHRCYP2C19KCNA5 | |
| SCHEMBL21758873 | 0.84 | CYP2D6 (0.54) | CYP3A4TSHRCYP2C19KCNA5GRIN2B | |
| SCHEMBL6577097 | 0.84 | GRIN2B (0.54) | CYP3A4TSHRCYP2C19KCNA5GRIN2B | |
| SCHEMBL597166 | 0.84 | CYP2D6 (0.54) | CYP3A4TSHRCYP2C19KCNA5GRIN2B | |
| SCHEMBL523547 | 0.84 | CYP2D6 (0.54) | CYP3A4TSHRCYP2C19KCNA5GRIN2B | |
| SCHEMBL21093474 | 0.84 | CYP2D6 (0.54) | CYP3A4TSHRCYP2C19KCNA5GRIN2B | |
| SCHEMBL21093518 | 0.84 | GRIN2B (0.54) | CYP3A4TSHRCYP2C19KCNA5GRIN2B | |
| SCHEMBL2712368 | 0.84 | CYP2D6 (0.54) | CYP3A4TSHRCYP2C19KCNA5GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250197421-A1 | MCL1 INHIBITORS | GILEAD SCIENCES, INC. | 2025-06-19 | — | — | US | disclosed |
| US-12202842-B2 | MCL1 inhibitors | GILEAD SCIENCES, INC. (US) | 2025-01-21 | — | — | US | disclosed |
| US-12091425-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2024-09-17 | — | — | US | disclosed |
| CN-114867530-B | MCL1 inhibitors | 吉利德科学公司 | 2024-08-16 | — | — | CN | disclosed |
| US-12024529-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-20230348494-A1 | MCL1 INHIBITORS | GILEAD SCIENCES, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230271981-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2023-08-31 | — | — | US | disclosed |
| US-11685747-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2023-06-27 | — | — | US | disclosed |
| US-11667652-B2 | MCL1 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| EP-3601297-B9 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC (US) | 2023-05-24 | — | — | EP | disclosed |
| US-20190016736-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2019-01-17 | — | — | US | disclosed |
| EP-3424931-A2 | TETRAHYDRONAPHTHALENE DERIVATIVES THAT INHIBIT MCL-1 PROTEIN | Amgen, Inc (US) | 2019-01-09 | — | — | EP | disclosed |
| EP-3186259-B1 | TETRAHYDRONAPHTHALENE DERIVATIVES THAT INHIBIT MCL-1 PROTEIN | AMGEN INC (US) | 2018-12-19 | — | — | EP | disclosed |
| US-10100063-B2 | Compounds that inhibit Mcl-1 protein | AMGEN INC. (US) | 2018-10-16 | — | — | US | disclosed |
| US-20180289720-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2018-10-11 | — | — | US | disclosed |
| US-20170088560-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2017-03-30 | — | — | US | disclosed |
| US-9562061-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2017-02-07 | — | — | US | disclosed |
| US-20160068545-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2016-03-10 | — | — | US | disclosed |
| US-20040236118-A1 | Pyrrolidine derivatives and method of synthesizing these | EIZAI CO., LTD (JP) | 2004-11-25 | — | — | US | disclosed |
| EP-1413574-A1 | PYRROLIDINE DERIVATIVES AND METHOD OF SYNTHESIZING THESE | Eizai Co., Ltd. (JP) | 2004-04-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180289720-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | MCL1, BCL9, BCL2L1 | CYP3A4 4129/4885ALDH1A1 1575/4885TSHR 4722/4885 |
| US-20230271981-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | MCL1, BCL2L1, BCL9 | CYP3A4 4076/4885ALDH1A1 1431/4885TSHR 4745/4885 |
| US-12202842-B2 | MCL1 inhibitors | MCL1, BCL2L1, BCLAF1 | CYP3A4 4386/4885ALDH1A1 887/4885TSHR 4537/4885 |
| US-20040236118-A1 | Pyrrolidine derivatives and method of synthesizing these | ADH1C, ADH5, ADH1A | CYP3A4 245/4885ALDH1A1 145/4885TSHR 2444/4885 |
| US-11685747-B2 | Compounds that inhibit MCL-1 protein | MCL1, BCL2L1, BCL9 | CYP3A4 4076/4885ALDH1A1 1431/4885TSHR 4745/4885 |
| US-20230348494-A1 | MCL1 INHIBITORS | MCL1, BCL2L1, BCLAF1 | CYP3A4 4459/4885ALDH1A1 946/4885TSHR 4551/4885 |
| US-12024529-B2 | Compounds that inhibit MCL-1 protein | MCL1, BCL2L1, BCL9 | CYP3A4 4076/4885ALDH1A1 1431/4885TSHR 4745/4885 |
| US-20160068545-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | MCL1, BCL9, BCL2L1 | CYP3A4 4326/4885ALDH1A1 1891/4885TSHR 4714/4885 |
| US-10100063-B2 | Compounds that inhibit Mcl-1 protein | MCL1, BCL9, BCL2L1 | CYP3A4 4326/4885ALDH1A1 1891/4885TSHR 4714/4885 |
| US-20250197421-A1 | MCL1 INHIBITORS | MCL1, BCL2L1, BCLAF1 | CYP3A4 4459/4885ALDH1A1 946/4885TSHR 4551/4885 |
| US-20190016736-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | MCL1, BCL2L1, BCL9 | CYP3A4 4076/4885ALDH1A1 1431/4885TSHR 4745/4885 |
| US-20170088560-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | MCL1, BCL9, BCL2L1 | CYP3A4 4326/4885ALDH1A1 1891/4885TSHR 4714/4885 |
| US-11667652-B2 | MCL1 inhibitors | MCL1, BCL2L1, BCLAF1 | CYP3A4 4459/4885ALDH1A1 946/4885TSHR 4551/4885 |
| US-12091425-B2 | Compounds that inhibit MCL-1 protein | MCL1, BCL9, BCL2L1 | CYP3A4 4326/4885ALDH1A1 1891/4885TSHR 4714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.